Skip to content

Study · Non-randomized trial · n = 13 · 1968

4 results

Assessment of long-acting synthetic corticotrophin in hypersensitive asthmatics and normal subjects.

el-Shaboury AH

British medical journal1 Sept 1968Cited by 18 (Europe PMC)

PMID4299775 (opens in a new tab)PMCIDPMC1986530 (opens in a new tab)DOI10.1136/bmj.3.5619.653 (opens in a new tab)PepBankPUB-04299775
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In normal subjects, depot-tetracosactrin and corticotrophin-gel were equally potent in raising plasma 17-OHCS.

    In plain wordsIn normal subjects, depot-tetracosactrin and corticotrophin-gel raised blood corticosteroids with equal potency.

    Peptide
    Cosyntropin
    Outcome
    Direction not reportedPlasma 17-OHCS response
    Study

    n = 13

    Comparator
    40 units corticotrophin-gel
    Outcome group
    Adrenal Function · Endocrine and hormones
    Studied dose
    1 mg and 0.5 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    In 13 normal subjects intramuscular injections of 1 mg. and 0.5 mg. of depot-tetracosactrin and 40 units of corticotrophin-gel were equally potent in raising the plasma 17-OHCS,
  2. 02HumanNon-randomized trialActivity measurement

    In normal subjects, depot-tetracosactrin had significantly longer action than corticotrophin-gel.

    In plain wordsIn normal subjects, depot-tetracosactrin acted significantly longer than corticotrophin-gel.

    Peptide
    Cosyntropin
    Outcome
    IncreaseDuration of corticosteroid response
    Study

    n = 13

    Comparator
    40 units corticotrophin-gel
    Outcome group
    Adrenal Function · Endocrine and hormones
    Studied dose
    1 mg and 0.5 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    but depot-tetracosactrin had a significantly longer action than corticotrophin-gel.
    1 context sentence
    Summary · context
    In 13 normal subjects intramuscular injections of 1 mg. and 0.5 mg. of depot-tetracosactrin and 40 units of corticotrophin-gel were equally potent in raising the plasma 17-OHCS,
  3. 03HumanNon-randomized trialEfficacy outcome

    Eight steroid-treated asthmatic patients had satisfactory plasma and urinary 17-OHCS increases after depot-tetracosactrin.

    In plain wordsEight asthmatic patients had satisfactory increases in blood and urine corticosteroids after depot-tetracosactrin.

    Peptide
    Cosyntropin
    Outcome
    Increase17-OHCS response
    Study

    n = 9

    Outcome group
    Adrenal Function · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Eight had a satisfactory increase in plasma and urinary 17-hydroxycorticosteroids (17-OHCS).
    1 context sentence
    Summary · context
    The synthetic polypeptide depot-tetracosactrin (Synacthen-Depot) was given to nine steroid-treated asthmatic patients hypersensitive to animal corticotrophin.
  4. 04HumanNon-randomized trialSafety outcome

    No hypersensitive asthmatic patient developed allergic reactions to depot-tetracosactrin.

    In plain wordsNo hypersensitive asthmatic patient developed allergic reactions to depot-tetracosactrin.

    Peptide
    Cosyntropin
    Outcome
    Not applicableAllergic reactions
    Study

    n = 9

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    None of the patients developed allergic reactions to depot-tetracosactrin,
    1 context sentence
    Summary · context
    The synthetic polypeptide depot-tetracosactrin (Synacthen-Depot) was given to nine steroid-treated asthmatic patients hypersensitive to animal corticotrophin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.